Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO invites bio prequalification

Executive Summary

An invitation to participate in a pilot procedure for the prequalification of both branded and biosimilar rituximab and trastuzumab has been published by the World Health Organization (WHO). First announced last year (Generics bulletin, 15 September 2017, page 5) – after the WHO announced that it would start prequalifying the two oncology treatments (Generics bulletin, 12 May 2017, page 13) – the scheme, titled ‘pilot procedure for prequalification of biotherapeutic products and similar biotherapeutic products’, has been billed by the WHO as “a step forward to support national and global efforts to increase access to and the affordability of biotherapeutic products and their corresponding similar biotherapeutic products”.

You may also be interested in...



WHO Prequalifies More Biosimilars

The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

WHO Prequalifies Celltrion’s Rituximab

Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

GB000928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel